In a class action defective drug lawsuit against Pfizer Inc, plaintiffs in Pennsylvania are challenging how drug manufacturers can promote their generic products.

The lawsuit claims that purchasers of the epilepsy drug Neruontin and its generic equivalent, gabapentin, were given as prescriptions for an off-label use. The case states that the drug manufacturer illegally promoted the drug by manipulating medical literature and by using other tactics, and should be liable to consumers who were prescribed generic versions of the drug.

Generic drugs must contain the same active ingredients as the original brand-name drug. The US Food and Drug Administration (FDA) states that generic drugs are identical, or the bioequivalent, to the brand name drugs. This means that generics are identical in dose, strength, safety, route of administration, and intended use. Generics are usually available once the patent protections of the original drug have expired.

Good drugs used like this are no better than defective drugs. If you or a loved one has been harmed, it is important that you consult with an expert defective drug attorney for professional insight.

This entry was posted on Tuesday, August 26th, 2008 at 3:11 pm and is filed under Blogroll, Defective Drugs, Safety. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.